Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis : A Randomized Clinical Trial
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis.
METHODS: A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy.
RESULTS: Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93-1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018).
CONCLUSIONS: Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.
CLINICAL TRIALS REGISTRATION: NCT01898338.
| Errataetall: |
CommentIn: Clin Infect Dis. 2021 May 4;72(9):1526-1528. - PMID 32887985 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 72(2021), 9 vom: 04. Mai, Seite 1517-1525 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
2N81MY12TE |
|---|
| Anmerkungen: |
Date Completed 20.05.2021 Date Revised 02.04.2024 published: Print ClinicalTrials.gov: NCT01898338 CommentIn: Clin Infect Dis. 2021 May 4;72(9):1526-1528. - PMID 32887985 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313008973 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313008973 | ||
| 003 | DE-627 | ||
| 005 | 20240402232324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1360.xml |
| 035 | |a (DE-627)NLM313008973 | ||
| 035 | |a (NLM)32725216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pujol, Miquel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis |b A Randomized Clinical Trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2021 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT01898338 | ||
| 500 | |a CommentIn: Clin Infect Dis. 2021 May 4;72(9):1526-1528. - PMID 32887985 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis | ||
| 520 | |a METHODS: A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy | ||
| 520 | |a RESULTS: Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93-1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018) | ||
| 520 | |a CONCLUSIONS: Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: NCT01898338 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a MRSA | |
| 650 | 4 | |a bacteremia | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a daptomycin | |
| 650 | 4 | |a fosfomycin | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Fosfomycin |2 NLM | |
| 650 | 7 | |a 2N81MY12TE |2 NLM | |
| 650 | 7 | |a Daptomycin |2 NLM | |
| 650 | 7 | |a NWQ5N31VKK |2 NLM | |
| 700 | 1 | |a Miró, José-María |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado, Jose-María |e verfasserin |4 aut | |
| 700 | 1 | |a San-Juan, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Puig-Asensio, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Pigrau, Carles |e verfasserin |4 aut | |
| 700 | 1 | |a Calbo, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Montejo, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Álvarez, Regino |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Pais, María-Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Pintado, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Escudero-Sánchez, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Contreras, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Morata, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, Milagros |e verfasserin |4 aut | |
| 700 | 1 | |a Andrés, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquau, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Arenas, María-Del-Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Padilla, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Murillas, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Jover-Sáenz, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a López-Cortes, Luis-Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a García-Pardo, Graciano |e verfasserin |4 aut | |
| 700 | 1 | |a Gasch, Oriol |e verfasserin |4 aut | |
| 700 | 1 | |a Videla, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Hereu, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Tebé, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Pallarès, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Sanllorente, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez, María-Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Càmara, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Padullés, Ariadna |e verfasserin |4 aut | |
| 700 | 1 | |a Cuervo, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Carratalà, Jordi |e verfasserin |4 aut | |
| 700 | 0 | |a MRSA Bacteremia (BACSARM) Trial Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Alex |e investigator |4 oth | |
| 700 | 1 | |a Almela, Manel |e investigator |4 oth | |
| 700 | 1 | |a Gómez, Frederic |e investigator |4 oth | |
| 700 | 1 | |a Chávez, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Mirelis, Beatriz |e investigator |4 oth | |
| 700 | 1 | |a Padilla, Emma |e investigator |4 oth | |
| 700 | 1 | |a Dolores Pérez-Ramírez, Maria |e investigator |4 oth | |
| 700 | 1 | |a Espasa, Mateu |e investigator |4 oth | |
| 700 | 1 | |a Maria Sánchez-Díaz, Ana |e investigator |4 oth | |
| 700 | 1 | |a Cercenado, Emilia |e investigator |4 oth | |
| 700 | 1 | |a Ruiz de Gopegui, Enrique |e investigator |4 oth | |
| 700 | 1 | |a Siverio, Ana |e investigator |4 oth | |
| 700 | 1 | |a de Cueto, Marina |e investigator |4 oth | |
| 700 | 1 | |a García-Garrote, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Mercè |e investigator |4 oth | |
| 700 | 1 | |a Xercavins, Mariona |e investigator |4 oth | |
| 700 | 1 | |a Nieves Larrosa, Maria |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 72(2021), 9 vom: 04. Mai, Seite 1517-1525 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2021 |g number:9 |g day:04 |g month:05 |g pages:1517-1525 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2021 |e 9 |b 04 |c 05 |h 1517-1525 | ||